South Korea
· Delayed Price · Currency is KRW Dong-A Socio Holdings Company Description
Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally.
It develops DA-1241 for the treatment of type 2 diabetes and non-alcoholic steatohepatitis; DA-1726, an oxyntomodulin analogue to treat obesity; DA-1229, a dipeptidyl peptidase-4 inhibitor class treatment for type 2 diabetes; DA-8010, a muscarinic M3 receptor antagonist for the treatment of overactive bladder; DMB-3115, a biosimilar of Stelara and an inflammatory disease treatment; DA-3880 to treat anemia; STP0404, an HIV-1 treatment drug; and STP1002, an anti-cancer drug.
The company also provides healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and derma business areas; CDMO services; imaging equipment and ENT workstation products; mineral water under the Cheonnyeonsu brand name; and IT and construction services.
In addition, it produces glass bottles, PET, and corrugated cardboard boxes; engages in the foundry equipment, logistics, and food and beverage businesses.
The company was founded in 1932 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 1932 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 5,530 |
| CEO | Jae-Hun Jung |
Contact Details
Address: 64, Cheonho-daero Seoul, 02587 South Korea | |
| Phone | 82 2 920 8114 |
| Website | donga.co.kr |
Stock Details
| Ticker Symbol | 000640 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7000640003 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jae-Hun Jung | Chief Executive Officer, Vice President and Inside Director |
| Seung Hyun Ko | Executive Director, Chief Financial Officer and Head of Management Support Office |
| Min-Woo Jo | Executive Director and Head of Management Planning Office |